Stock Analiz

Senti Biosciences Holdings, Inc. SNTI

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026

$0.14Market cap $5M
Open the interactive analysis →

Senti Biosciences Holdings, Inc. (SNTI) is a healthcare company listed in the US with a market value of about $5M. In the twelve months to June 30, 2026 it had revenue of $55000 and net income of -$50M, a net margin of -90116.4%.

Its overall Stock Analiz score is 0.2 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -85%.

About Senti Biosciences

Senti Biosciences is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. Revenue went from $3M in 2021 to $22000 in 2025, a decline of about 70.1% a year. It was profitable in 0 of the last 5 years in our data. Its share count rose by 761% over three years (dilution for shareholders). It spends 170845% of revenue on research and development.

Score: 0.2 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health0/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S97.9
P/B—
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-706.8%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-99.7%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-57247.1%
ROIC (5-yr avg.)-84.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 5 years

Fiscal yearTTM20252024202320222021
Revenue$55000$22000$7M$3M$4M$3M
Net income-$50M-$61M-$53M-$71M-$58M-$55M
Free cash flow-$38M-$44M-$41M-$64M-$76M-$40M
EPS (diluted)$-1.72$-2.73$-12.03$-16.01$-22.30$-190.00
Net margin-90116.4%-279300.0%-798.9%-2774.6%-1358.1%-2003.6%
ROIC—-157.6%-81.5%-70.1%-29.8%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Senti Biosciences pay a dividend?

Not currently.

Is Senti Biosciences a good stock to buy?

We do not give buy or sell advice. Senti Biosciences scores 0.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.